Market Exclusive

Analyst Activity – Chardan Capital Initiates Coverage On Arbutus Biopharma (NASDAQ:ABUS) With a Buy

Analyst Ratings For Arbutus Biopharma (NASDAQ:ABUS)

Today, Chardan Capital initiated coverage on Arbutus Biopharma (NASDAQ:ABUS) with a Buy with a price target of $8.25.

Some recent analyst ratings include

Recent Insider Trading Activity For Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ:ABUS) has insider ownership of 6.90% and institutional ownership of 62.14%.

Recent Trading Activity for Arbutus Biopharma (NASDAQ:ABUS)
Shares of Arbutus Biopharma closed the previous trading session at with 5.050000190734863 shares trading hands.

Exit mobile version